Home>Topics>Stocks>Holly Energy Partners

Holly Energy Partners HEP

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study

      Headlines

      Thu, 26 Feb 2015

      Feb 26 (Reuters) - Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and...

    2. UPDATE 1-Australian food company recalls berries after hep A outbreak linked to China

      Headlines

      Mon, 16 Feb 2015

      * Patties says too early to estimate financial impact (Updates with new cases, quote, more cases expected)

    3. Australian food company recalls berries after hep A outbreak linked to China

      Headlines

      Sun, 15 Feb 2015

      SYDNEY, Feb 16 (Reuters) - An Australian company has recalled its frozen berry products following a hepatitis A outbreak linked to poor hygiene and water supplies in a Chinese packaging plant,...

    4. Australia's Patties Foods shares slide after hep A outbreak linked to China

      Headlines

      Sun, 15 Feb 2015

      SYDNEY, Feb 16 (Reuters) - Shares in Australia's Patties Foods Ltd fell as much as 18 percent on Monday after it recalled its frozen berry products following a hepatitis A outbreak that has been...

    5. Gilead agrees 41,000 eur hep -C drug price for 12 week treatment

      Headlines

      Thu, 12 Feb 2015

      FRANKFURT, Feb 12 (Reuters) - Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the...

    6. Gilead expects big increase in Europeans treated with hep C drug

      Headlines

      Tue, 10 Feb 2015

      NEW YORK, Feb 10 (Reuters) - Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly.

    7. Gilead faces challenge to European patent on pricey hep C drug

      Headlines

      Tue, 10 Feb 2015

      LONDON, Feb 10 (Reuters) - Global health charity Medecins du Monde (MdM) launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of charging "exorbitant" prices for a hepatitis C drug.

    8. UPDATE 2-Promising data bodes well for all-Achillion hep C treatment

      Headlines

      Mon, 9 Feb 2015

      * Study shows Achillion's inhibitor looks best-in-class: analyst

    9. Merck's 4Q and Guidance Largely Meet Expectations, but Headwinds Arise For Hep C Drugs and Remicade

      Commentary

      Wed, 4 Feb 2015

      Merck reported fourth-quarter results and issued 2015 guidance largely in line with both our and consensus expectations and we don't expect any changes to our fair value estimate. However, the loss of the FDA's Breakthrough Therapy Designation for Merck's hepatitis C treatment (due to recently ...

    10. Gilead 4th-qtr profit quadruples, $3.84 bln in hep C drug sales

      Headlines

      Tue, 3 Feb 2015

      Feb 3 (Reuters) - Gilead Sciences Inc posted strong quarterly sales of its hepatitis C drugs Harvoni and Sovaldi, sending the drugmaker's net profit up more than four-fold for the quarter.

    « Prev12345Next »
    Content Partners